Anika Therapeutics, Inc. Expands Strategic Collaboration with the Institute for Applied Life Sciences to Develop Innovative Therapy for Rheumatoid Arthritis
January 24, 2018 at 09:05 pm
Share
A new agreement to extend a two-year-long strategic collaboration that yielded a promising new modality for the treatment of rheumatoid arthritis (RA) was announced by Anika Therapeutics, Inc., and the Institute for Applied Life Sciences at the University of Massachusetts (UMass) Amherst. In the next phase of this collaboration, Anika and UMass will focus on research to optimize the drug delivery system with the goal of advancing a novel therapeutic candidate into clinical trials to support regulatory submission.
Anika Therapeutics, Inc. is a joint preservation company focused on developing, manufacturing, and commercializing products based on hyaluronic acid (HA) technology platform. The OA Pain Management product family consists of Monovisc and Orthovisc that provides pain relief from osteoarthritis conditions and Cingal consisting of its cross-linked HA material combined with a fast-acting steroid. Its Joint Preservation and Restoration product family consists of its portfolio of orthopedic regenerative solutions products: Integrity, Tactoset, and Hyalofast; its line of sports medicine solutions repairs and reconstructs damaged ligaments and tendons, and its Arthrosurface portfolio of bone preserving joint technologies, including partial joint replacement, joint resurfacing, and minimally invasive and bone sparing implants. Its Non-Orthopedic product family provides orthopedic applications, including adhesion barrier product, advanced wound care products, and ear, nose and throat products.
Anika Therapeutics, Inc. Expands Strategic Collaboration with the Institute for Applied Life Sciences to Develop Innovative Therapy for Rheumatoid Arthritis
ANIKA THERAPEUTICS, INC. 
